Updated

Yale researchers found that lacosamide, an FDA-approved epilepsy drug, blocks a protein involved in both pain signaling and cartilage destruction, helping damaged joints shift toward repair in preclinical studies—suggesting a potential new approach to osteoarthritis treatment beyond pain relief.